Comparison Of Drugs Approved For CLL & SLL
Chart highlights differences for three drugs newly approved by FDA, based mostly on labeling, compared to two traditional anti-CD20 antibody options: Roche’s Rituxan and GSK’s Arzerra.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.